Trial · NCT02010567
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of CRLX101 When Added to Standard Neoadjuvant Chemoradiotherapy Consisting of Capecitabine + Radiotherapy in Locally Advanced Rectal Cancer | Dose Escalation Phase Ib | 15 | mg/m^2 every other week | ||
| Pathological Complete Response (pCR) Rate | All Participants | 19 | 95% Confidence Interval 7 to 36 | percentage of participants with pCR | |
| Pathological Response Rate | All Participants | pCR | 6 | Participants | |
| Pathological Response Rate | All Participants | Moderate response | 18 | Participants | |
| Pathological Response Rate | All Participants | Minimal response | 7 | Participants | |
| Pathological Response Rate | All Participants | Unknown | 1 | Participants | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | Colitis | 1 | participants with AE | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | Dermatitis, radiation | 1 | participants with AE | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | Diarrhea | 1 | participants with AE | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | Hypophosphatemia | 1 | participants with AE | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | Lymphocyte count decreased | 9 | participants with AE | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | Rectal obstruction | 1 | participants with AE | |
| Number of Participants With Grade 3 or Higher, Treatment-related Toxicities | All Participants | White blood cell decreased | 1 | participants with AE | |
| Disease-free Survival (DFS) Rate | Cohort A, Phase II, Dose Level 2 | 10 | Participants | ||
| Overall Survival (OS) Rate | Cohort A, Phase II, Dose Level 2 | 13 | Participants | ||
| Disease-free Survival (DFS) Rate Based on Pathological Complete Response (pCR). | Cohort A, Phase II, Dose Level 2 | pathological complete response (pCR) | 2 | Participants | |
| Disease-free Survival (DFS) Rate Based on Pathological Complete Response (pCR). | Cohort A, Phase II, Dose Level 2 | Did not achieve pCR | 8 | Participants | |
| Overall Survival (OS) Based on Pathological Complete Response (pCR). | Cohort A, Phase II, Dose Level 2 | pathological complete response (pCR) | 2 | Participants | |
| Overall Survival (OS) Based on Pathological Complete Response (pCR). | Cohort A, Phase II, Dose Level 2 | Did not achieve pCR | 11 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02010567/results